Ponatinib

CAS 943319-70-8Small Molecule

Overview

Ponatinib is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1171837).

Patent & exclusivity (US)

Per the FDA Orange Book (4 approved US products), the latest listed US patent on Ponatinib expires 12 Dec 2033 and exclusivity 19 Mar 2031. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name
3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide
Canonical SMILES
CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5
InChIKey
PHXJVRSECIGDHY-UHFFFAOYSA-N
Verified Supplier Partner

Do you supply Ponatinib? Get in front of buyers actively sourcing it.

We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.

No cost to enquire · we only reach out with a fit.

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.